TY - JOUR
T1 - Activation of the Protective Arm of the Renin Angiotensin System in Demyelinating Disease
AU - Stone, Roslynn E.
AU - Liu, Siyu
AU - Levy, Alexander M.
AU - Kashani, Nicole
AU - Louie, Stan G.
AU - Rodgers, Kathleen E.
AU - Kelland, Eve E.
AU - Lund, Brett T.
N1 - Funding Information:
This work was supported by the Department of Defense (Grant No. MS130053 ? BTL). MS brain specimens were obtained from the Human Brain and Spinal Fluid Resource Center, which is sponsored by NINDS/NIMH, National Multiple Sclerosis Society, VA Greater Los Angeles Healthcare System, 11301 Wilshire Blvd. Los Angeles, CA 90073, and Veterans Health Services and Research Administration, Department of Veterans Affairs.
Funding Information:
This work was supported by the Department of Defense (Grant No. MS130053 - BTL). Acknowledgements
Publisher Copyright:
© 2019, Springer Science+Business Media, LLC, part of Springer Nature.
PY - 2020/6/1
Y1 - 2020/6/1
N2 - The renin angiotensin system (RAS), which is classically known for blood pressure regulation, has functions beyond this. There are two axes of RAS that work to counterbalance each other and are active throughout the body, including the CNS. The pathological axis, consisting of angiotensin II (A1-8), angiotensin converting enzyme (ACE) and the angiotensin II type 1 receptor (AT1R), is upregulated in many CNS diseases, including multiple sclerosis (MS). MS is an autoimmune and neurodegenerative disease of the CNS characterized by inflammation, demyelination and axonal degeneration. Published research has described increased expression of AT1R and ACE in tissues from MS patients and in animal models of MS such as experimental autoimmune encephalomyelitis (EAE). In contrast to the pathological axis, little is known about the protective axes of RAS in MS and EAE. In other neurological conditions the protective axis, which includes A1–7, ACE2, angiotensin II type 2 receptor and Mas receptor, has been shown to have anti-inflammatory, regenerative and neuroprotective effects. Here we show, for the first time, changes in the protective arm of RAS in both EAE and MS CNS tissue. We observed a significant increase in expression of the protective arm during stages of disease stabilization in EAE, and in MS tissue showing evidence of remyelination. These data provide evidence that the protective arm of RAS, through both ligand and receptor expression, is associated with reductions in the pathological processes that occur in the earlier stages of MS and EAE, possibly slowing the neurodegenerative process and enhancing neural repair. [Figure not available: see fulltext.].
AB - The renin angiotensin system (RAS), which is classically known for blood pressure regulation, has functions beyond this. There are two axes of RAS that work to counterbalance each other and are active throughout the body, including the CNS. The pathological axis, consisting of angiotensin II (A1-8), angiotensin converting enzyme (ACE) and the angiotensin II type 1 receptor (AT1R), is upregulated in many CNS diseases, including multiple sclerosis (MS). MS is an autoimmune and neurodegenerative disease of the CNS characterized by inflammation, demyelination and axonal degeneration. Published research has described increased expression of AT1R and ACE in tissues from MS patients and in animal models of MS such as experimental autoimmune encephalomyelitis (EAE). In contrast to the pathological axis, little is known about the protective axes of RAS in MS and EAE. In other neurological conditions the protective axis, which includes A1–7, ACE2, angiotensin II type 2 receptor and Mas receptor, has been shown to have anti-inflammatory, regenerative and neuroprotective effects. Here we show, for the first time, changes in the protective arm of RAS in both EAE and MS CNS tissue. We observed a significant increase in expression of the protective arm during stages of disease stabilization in EAE, and in MS tissue showing evidence of remyelination. These data provide evidence that the protective arm of RAS, through both ligand and receptor expression, is associated with reductions in the pathological processes that occur in the earlier stages of MS and EAE, possibly slowing the neurodegenerative process and enhancing neural repair. [Figure not available: see fulltext.].
KW - Angiotensin (1–7)
KW - Angiotensin II type II receptor (AT2R)
KW - Mas receptor
KW - Multiple sclerosis (MS)
KW - Renin angiotensin system (RAS)
UR - http://www.scopus.com/inward/record.url?scp=85076435307&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85076435307&partnerID=8YFLogxK
U2 - 10.1007/s11481-019-09894-7
DO - 10.1007/s11481-019-09894-7
M3 - Article
C2 - 31828731
AN - SCOPUS:85076435307
SN - 1557-1890
VL - 15
SP - 249
EP - 263
JO - Journal of NeuroImmune Pharmacology
JF - Journal of NeuroImmune Pharmacology
IS - 2
ER -